Study of effect of oral itraconazole with 2% sertaconazole cream versus oral terbinafine with 2% sertaconazole cream in dermatophytosis

Ayesha Sharmeen, S. Amin, M. Adil, Iti Varshney
{"title":"Study of effect of oral itraconazole with 2% sertaconazole cream versus oral terbinafine with 2% sertaconazole cream in dermatophytosis","authors":"Ayesha Sharmeen, S. Amin, M. Adil, Iti Varshney","doi":"10.18203/issn.2455-4529.intjresdermatol20232542","DOIUrl":null,"url":null,"abstract":"Background: Dermatophytosis is a common dermatological problem. Recent studies have reported an increase in the prevalence of the disease. Management of dermatophytosis thus has become challenging for both dermatologists and patients due to their resistance to treatment and their refractory nature. Currently the management of dermatophytic infection includes both oral and topical antifungals. The study compared the clinical efficacy and adverse effect profile of systemic with topical drugs.\nMethods: Patients were randomly divided into two groups of 90 each. They were given oral Itraconazole 100 mg twice daily with Sertaconazole 2 % cream twice daily (Group A) and oral Terbinafine 250 mg once daily with Sertaconazole 2 % cream twice daily (Group B) till complete resolution of lesions or a maximum of six weeks. The response was assessed by the improvement in signs and symptoms of each of the clinical parameter, pruritus, erythema, scaling. \nResults: At week 6, mycological cure was seen in 92.9% in Group A as compared to 86.9% of patients in Group B. There was a significant improvement in percentage change in pruritus, erythema, and scaling in both the groups from 0 to 6 weeks (p-value: <0.0001). Mild adverse effects such as gastrointestinal upset, headache, and raised transaminases were observed which were comparable in both the groups. \nConclusions: On comparison of the groups, we observed that both were effective but Itraconazole with Sertaconazole 2% cream was more efficacious in terms of both clinical (pruritus, scaling, and erythema) and mycological cure.","PeriodicalId":14331,"journal":{"name":"International Journal of Research in Dermatology","volume":"285 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Research in Dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18203/issn.2455-4529.intjresdermatol20232542","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Dermatophytosis is a common dermatological problem. Recent studies have reported an increase in the prevalence of the disease. Management of dermatophytosis thus has become challenging for both dermatologists and patients due to their resistance to treatment and their refractory nature. Currently the management of dermatophytic infection includes both oral and topical antifungals. The study compared the clinical efficacy and adverse effect profile of systemic with topical drugs. Methods: Patients were randomly divided into two groups of 90 each. They were given oral Itraconazole 100 mg twice daily with Sertaconazole 2 % cream twice daily (Group A) and oral Terbinafine 250 mg once daily with Sertaconazole 2 % cream twice daily (Group B) till complete resolution of lesions or a maximum of six weeks. The response was assessed by the improvement in signs and symptoms of each of the clinical parameter, pruritus, erythema, scaling. Results: At week 6, mycological cure was seen in 92.9% in Group A as compared to 86.9% of patients in Group B. There was a significant improvement in percentage change in pruritus, erythema, and scaling in both the groups from 0 to 6 weeks (p-value: <0.0001). Mild adverse effects such as gastrointestinal upset, headache, and raised transaminases were observed which were comparable in both the groups. Conclusions: On comparison of the groups, we observed that both were effective but Itraconazole with Sertaconazole 2% cream was more efficacious in terms of both clinical (pruritus, scaling, and erythema) and mycological cure.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
口服伊曲康唑加2%舍他康唑乳膏与口服特比萘芬加2%舍他康唑乳膏治疗皮肤癣的疗效比较
背景:皮肤真菌病是一种常见的皮肤病。最近的研究报告说,这种疾病的流行率有所上升。因此,由于对治疗的抵抗力和难治性,皮肤癣的治疗对皮肤科医生和患者都具有挑战性。目前,皮肤真菌感染的治疗包括口服和局部抗真菌药物。本研究比较了全身用药和局部用药的临床疗效和不良反应。方法:将患者随机分为两组,每组90例。A组患者口服伊曲康唑100 mg,每日2次,合并舍他康唑2%乳膏,每日2次;B组患者口服特比萘芬250 mg,每日1次,合并舍他康唑2%乳膏,每日2次,直至病灶完全消退或最多6周。反应是通过改善体征和症状的每一个临床参数,瘙痒,红斑,脱屑。结果:第6周时,A组患者的真菌学治愈率为92.9%,b组为86.9%。两组患者瘙痒、红斑和结垢的百分比变化从0周到6周显著改善(p值:<0.0001)。轻微的不良反应,如胃肠道不适、头痛和转氨酶升高,在两组中都有可比性。结论:在两组比较中,我们观察到两组均有效,但伊曲康唑与舍他康唑2%乳膏在临床(瘙痒、结垢和红斑)和真菌学治疗方面更有效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Dupilumab as a treatment for a case of benign familial pemphigus A phase III randomized controlled clinical trial evaluating the efficacy and safety of naftifine 2% cream versus terbinafine 1% cream in patients with superficial fungal infection of the skin Tofaticinib as a potential therapeutic agent: a review The evaluation of serum vitamin D3 in androgenetic alopecia: a case-control study Aleukemic leukemia cutis: a rare case report
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1